C H Adler

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study
    Charles H Adler
    From the Parkinson s Disease and Movement Disorders Center, Department of Neurology C H A, J N C, E D D, and Department of Biostatistics J G H, Mayo Clinic, Scottsdale Civin Laboratory for Neuropathology T G B, L I S, B N D and Cleo Roberts Center H A S, M N S, S A J, C M B, Banner Sun Health Research Institute, Sun City, AZ and University of Arizona College of Medicine H A S, M N S, S A J, Phoenix
    Neurology 83:406-12. 2014
  2. pmc Disassembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson's disease patients
    Zhenyu Zhong
    Haldeman Laboratory of Molecular and Cellular Neurobiology, Sun Health Research Institute, Sun City, AZ USA
    Mol Neurodegener 4:30. 2009
  3. pmc Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)
    Joseph Jankovic
    Baylor College of Medicine, Department of Neurology, Houston, TX, USA
    BMC Neurol 11:140. 2011
  4. ncbi request reprint Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Mov Disord 18:287-93. 2003
  5. ncbi request reprint Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Parkinsonism Relat Disord 9:103-10. 2002
  6. pmc Essential tremor and Parkinson's disease: lack of a link
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Mov Disord 26:372-7. 2011
  7. ncbi request reprint Nonmotor complications in Parkinson's disease
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Mov Disord 20:S23-9. 2005
  8. pmc Incidental Lewy body disease: clinical comparison to a control cohort
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Mov Disord 25:642-6. 2010
  9. ncbi request reprint Ropinirole for restless legs syndrome: a placebo-controlled crossover trial
    C H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, AZ 85259, USA
    Neurology 62:1405-7. 2004
  10. pmc Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome
    Charles H Adler
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Parkinsonism Relat Disord 17:456-8. 2011

Detail Information

Publications66

  1. ncbi request reprint Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study
    Charles H Adler
    From the Parkinson s Disease and Movement Disorders Center, Department of Neurology C H A, J N C, E D D, and Department of Biostatistics J G H, Mayo Clinic, Scottsdale Civin Laboratory for Neuropathology T G B, L I S, B N D and Cleo Roberts Center H A S, M N S, S A J, C M B, Banner Sun Health Research Institute, Sun City, AZ and University of Arizona College of Medicine H A S, M N S, S A J, Phoenix
    Neurology 83:406-12. 2014
    ..Determine diagnostic accuracy of a clinical diagnosis of Parkinson disease (PD) using neuropathologic diagnosis as the gold standard...
  2. pmc Disassembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson's disease patients
    Zhenyu Zhong
    Haldeman Laboratory of Molecular and Cellular Neurobiology, Sun Health Research Institute, Sun City, AZ USA
    Mol Neurodegener 4:30. 2009
    ..ABSTRACT: Correction to Nural H, He P, Beach T, Sue L, Xia W, Shen Y. Disassembled DJ-1 high molecular weight complex in cortex mitochondria from Parkinson's disease patients Molecular Neurodegeneration 2009, 4:23...
  3. pmc Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)
    Joseph Jankovic
    Baylor College of Medicine, Department of Neurology, Houston, TX, USA
    BMC Neurol 11:140. 2011
    ..Irvine, CA, USA). Methods and baseline demographics from an interim analysis are provided...
  4. ncbi request reprint Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Mov Disord 18:287-93. 2003
    ..Our data demonstrate that, in a small sample size, administration of 200 mg/day of modafinil was associated with few side effects and was modestly effective for the treatment of excessive daytime sleepiness in patients with PD...
  5. ncbi request reprint Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Parkinsonism Relat Disord 9:103-10. 2002
    ..This study underscores the importance of longitudinal antemortem testing of prospective brain donors as well as the potential value of quantitative motor testing...
  6. pmc Essential tremor and Parkinson's disease: lack of a link
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Mov Disord 26:372-7. 2011
    ..Essential tremor (ET) is a very common disorder and proving that there is a relationship to another common movement disorder, Parkinson's disease (PD), has been debated for years...
  7. ncbi request reprint Nonmotor complications in Parkinson's disease
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Mov Disord 20:S23-9. 2005
    ..This review will discuss many of the nonmotor complications in PD, including cognitive, autonomic, sleep, and sensory difficulties that may occur...
  8. pmc Incidental Lewy body disease: clinical comparison to a control cohort
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Mov Disord 25:642-6. 2010
    ..Larger sample size is needed to have the power to better assess group differences...
  9. ncbi request reprint Ropinirole for restless legs syndrome: a placebo-controlled crossover trial
    C H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, AZ 85259, USA
    Neurology 62:1405-7. 2004
    ..Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS...
  10. pmc Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome
    Charles H Adler
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Parkinsonism Relat Disord 17:456-8. 2011
    ..Compare the frequency of REM sleep behavior disorder (RBD) and excessive daytime sleepiness (EDS) in Parkinson's disease (PD), restless legs syndrome (RLS), essential tremor (ET), and control subjects...
  11. ncbi request reprint Abnormal co-contraction in yips-affected but not unaffected golfers: evidence for focal dystonia
    C H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
    Neurology 64:1813-4. 2005
  12. ncbi request reprint Botulinum toxin type A for treating voice tremor
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Arch Neurol 61:1416-20. 2004
    ..Voice tremor, like spasmodic dysphonia and other tremor disorders, may respond to botulinum toxin type A injections...
  13. ncbi request reprint Strategies for controlling dystonia. Overview of therapies that may alleviate symptoms
    C H Adler
    Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA
    Postgrad Med 108:151-2, 155-6, 159-60. 2000
    ..Surgical treatment of dystonia may be performed peripherally or centrally but is usually reserved for patients in whom other forms of therapy fail...
  14. ncbi request reprint Sleep issues in Parkinson's disease
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ 85256, USA
    Neurology 64:S12-20. 2005
    ..Effective management of sleep disturbances and excessive daytime sleepiness can greatly improve the quality of life for patients with PD...
  15. ncbi request reprint Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Mov Disord 17:158-61. 2002
    ..We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period...
  16. ncbi request reprint Relevance of motor complications in Parkinson's disease
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
    Neurology 58:S51-6. 2002
    ..Overall, quality of life suffers. In addition, there is a marked increase in the expense to both the patient and society when motor fluctuations and dyskinesias develop...
  17. doi request reprint Premotor symptoms and early diagnosis of Parkinson's disease
    Charles H Adler
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Int J Neurosci 121:3-8. 2011
    ..What is becoming increasingly clear is that nonmotor findings, including hyposmia, sleep disorders, autonomic abnormalities, cognitive changes, and neurobehavioral changes, often precede the motor findings...
  18. doi request reprint Are the yips a task-specific dystonia or "golfer's cramp"?
    Charles H Adler
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
    Mov Disord 26:1993-6. 2011
    ..2%). Golfers with video evidence of an involuntary movement while putting have excessive rotation of the right wrist in a pronation/supination motion and, as previously reported, a trend for wrist flexor/extensor cocontraction...
  19. ncbi request reprint Perioperative use of botulinum toxins
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic, Department of Neurology, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Toxicon 54:654-7. 2009
    ..Botulinum toxins are not commonly thought of as adjuncts to surgical procedures. This article reviews some of the perioperative uses of botulinum toxins...
  20. pmc Quantitative EEG as a predictive biomarker for Parkinson disease dementia
    B T Klassen
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Neurology 77:118-24. 2011
    ..A reliable predictive QEEG biomarker for PD dementia (PD-D) incidence would be valuable for studying PD-D, including treatment trials aimed at preventing cognitive decline in PD...
  21. ncbi request reprint Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease
    J N Caviness
    Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ, USA
    Parkinsonism Relat Disord 13:348-54. 2007
    ..PD-MCI has mean quantitative EEG characteristics that represent an intermediate electrophysiological state between PD-CogNL and PD-D...
  22. ncbi request reprint Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease
    M N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, Sun City, AZ 85351, USA
    Dement Geriatr Cogn Disord 24:327-34. 2007
    ..We now determine if the correlation between cognitive impairment and functional ability in PD is similar to that in AD using individual cognitive measures...
  23. ncbi request reprint Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson's disease
    V G H Evidente
    Department of Neurology Department of Neurological Surgery, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Acta Neurol Scand 124:211-4. 2011
    ..To compare the medication dose reduction between deep brain stimulation (DBS) of the globus pallidus interna (GPi) vs subthalamic nucleus (STN) in matched patients with Parkinson's disease (PD)...
  24. ncbi request reprint Electrophysiology of the myoclonus in dementia with Lewy bodies
    J N Caviness
    Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA
    Neurology 60:523-4. 2003
  25. ncbi request reprint A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor
    M F Brin
    Department of Neurology, Columbia University, New York, NY, USA
    Neurology 56:1523-8. 2001
    ..Hand weakness is a dose-dependent significant side effect of treatment at the doses used in this study...
  26. doi request reprint Pathologic findings in prospectively ascertained essential tremor subjects
    H A Shill
    Sun Health Research Institute, Sun City, AZ, USA
    Neurology 70:1452-5. 2008
    ..To assess pathologic changes in prospectively characterized subjects with essential tremor (ET)...
  27. ncbi request reprint Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease?
    M N Sabbagh
    The Cleo Roberts Center for Clinical Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Parkinsonism Relat Disord 11:311-5. 2005
    ..647, P<0.001, respectively). The UPDRS correlated with the GDS and FAST more closely in PD than in AD. Similar to AD, functional declines in PD correlates with cognitive decline and may be influenced by motor disability in PD...
  28. ncbi request reprint Case studies in movement disorders
    Virgilio Gerald H Evidente
    Movement Disorders Division, Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Semin Neurol 23:277-84. 2003
    ..A detailed discussion of botulinum toxin follows the case on cervical dystonia, focusing on its mechanism of action, clinical indications, side effects, and dosing...
  29. ncbi request reprint Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors
    J N Joyce
    Thomas H Christopher Center for Parkinson s Disease Research, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Brain Res 955:138-52. 2002
    ..Thus, loss of dopamine D(3) receptors may be a more important contributing factor to a loss of response to dopaminergic drugs than changes in the D(2) receptor...
  30. ncbi request reprint Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
    J Jankovic
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA
    Neurology 67:2233-5. 2006
    ..One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy...
  31. ncbi request reprint Motor unit number estimates in idiopathic Parkinson's disease
    J N Caviness
    Department of Neurology, Mayo Clinic Scottsdale, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA
    Parkinsonism Relat Disord 8:161-4. 2002
    ..Progress in decreasing the variance of MUNEs will facilitate their use in detecting small motor unit number changes in neurodegenerative disease...
  32. ncbi request reprint Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease
    John N Caviness
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mov Disord 21:492-9. 2006
    ..The small amplitude postural tremor in PD arises from heterogeneous oscillator mechanisms. The discovery of increased corticomuscular coupling shows cortical involvement in the small amplitude postural tremor of PD...
  33. ncbi request reprint Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma
    Steven Vernino
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Neurol 51:625-30. 2002
    ..Four patients improved with chemotherapy, and 2 improved with intravenous methylprednisolone...
  34. ncbi request reprint Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease
    John N Caviness
    Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA
    Mov Disord 18:1157-62. 2003
    ..These results have mechanistic implications for cortical dysfunction in Parkinson's disease and for cortical myoclonus in general...
  35. doi request reprint Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia
    Amy C Almaraz
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Neurologist 15:234-7. 2009
    ..Therefore, cholinesterase inhibitors might improve cognitive function in PDD. On the other hand, enhancing cholinergic function could plausibly worsen features of parkinsonism...
  36. doi request reprint An update on the neurologic applications of botulinum toxins
    Virgilio Gerald H Evidente
    Department of Neurology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Curr Neurol Neurosci Rep 10:338-44. 2010
    ..This article highlights some of the common neurologic conditions currently improved by botulinum toxins and reviews the scientific evidence from research studies and clinical experience with these conditions...
  37. doi request reprint Parkinson's disease dementia and potential therapeutic strategies
    John N Caviness
    Mayo Clinic College of Medicine, Mayo Clinic, USA
    CNS Neurosci Ther 17:32-44. 2011
    ..More research is needed on the specific aspects of cortical dysfunction and degeneration that create PD-D...
  38. ncbi request reprint The 'yips' in golf: a continuum between a focal dystonia and choking
    Aynsley M Smith
    Sports Medicine Center, Mayo Clinic, Rochester, Minnesota 55905, USA
    Sports Med 33:13-31. 2003
    ..A theoretical model provides a guide for future research on golfers with either type I or type II 'yips'...
  39. ncbi request reprint Small-amplitude cortical myoclonus in Parkinson's disease: physiology and clinical observations
    John N Caviness
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA
    Mov Disord 17:657-62. 2002
    ..Although the myoclonus occurred without dementia in these cases, its relationship to the subsequent development of cognitive impairment remains to be defined...
  40. ncbi request reprint Myoclonus in Lewy body disorders
    John N Caviness
    Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Adv Neurol 89:23-30. 2002
  41. ncbi request reprint Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome
    Erika D Driver-Dunckley
    Department of Neurology, Parkinson s Disease and Movement Disorders Center, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Clin Neuropharmacol 30:249-55. 2007
    ..Do patients with restless legs syndrome (RLS) report gambling or other abnormal behaviors as previously reported in Parkinson disease...
  42. ncbi request reprint Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Mov Disord 19:1075-9. 2004
    ..Breathiness was the most common side effect but was mild in intensity and of short duration. We conclude that BoNT-B is safe and effective for the treatment of adductor spasmodic dysphonia...
  43. ncbi request reprint The patient with Parkinson's disease: part I-treating the motor symptoms; part II-treating the nonmotor symptoms
    Charlene Hoffman Snyder
    Department of Neurology, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
    J Am Acad Nurse Pract 19:179-97. 2007
    ..The discussion provides treatment strategies that may offer improved ability to manage the disabling symptoms of this neurodegenerative disorder...
  44. ncbi request reprint Defining mild cognitive impairment in Parkinson's disease
    John N Caviness
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
    Mov Disord 22:1272-7. 2007
    ..Defining PD-MCI offers an opportunity for further study of cognitive impairment in PD and targets for earlier therapeutic intervention...
  45. ncbi request reprint Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss
    V G Evidente
    Mayo Clinic Scottsdale, Scottsdale, Arizona 85259, USA
    Mov Disord 16:924-7. 2001
    ..The results indicate that unintended weight loss in PD patients is unlikely to be due to abnormal serum leptin concentrations...
  46. ncbi request reprint Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders?
    Jonathan H McKinnon
    Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Neurologist 13:382-5. 2007
    ..A recent American Academy of Neurology practice parameter indicated that olfactory testing was "probably useful" for differentiating idiopathic Parkinson disease (IPD) from other diseases with features of parkinsonism...
  47. ncbi request reprint Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm
    S J Johnstone
    Department of Neurology, Barrow Neurologic Institute, Phoenix, AZ 85013, USA
    Headache 38:366-8. 1998
    ..This patient illustrates the importance of looking for blepharospasm in patients who present with headache or face pain, as her pain and blepharospasm were successfully treated with botulinum toxin type A injections...
  48. ncbi request reprint Restless legs syndrome in Parkinson's disease patients may improve with subthalamic stimulation
    Erika Driver-Dunckley
    Department of Neurology, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Mov Disord 21:1287-9. 2006
    ..Despite a mean 56% decrease in their levodopa equivalents postoperatively, their RLS scores dropped by a mean of 84% (100% in three). Our findings suggest that bilateral STN DBS surgery can improve RLS in patients with advanced PD...
  49. ncbi request reprint Altered aiming movements in Parkinson's disease patients and elderly adults as a function of delays in movement onset
    Diana H Romero
    Motor Control Laboratory, Arizona State University, Arizona, USA
    Exp Brain Res 151:249-61. 2003
    ..It can be inferred from the results that the decay in position sense as a function of time produces impairments in incorporating the initial limb position in motor planning process...
  50. pmc Characterization of DCTN1 genetic variability in neurodegeneration
    C Vilariño-Güell
    Molecular Genetics Laboratory and Core, Morris K Udall Parkinson s Disease Research Center of Excellence, Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Neurology 72:2024-8. 2009
    ....
  51. ncbi request reprint Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial
    Arthur S Walters
    Department of Neurology, Vanderbilt University Medical Center, 1161 21st Ave, Nashville, TN 37232 2551, USA
    Clin Neuropharmacol 32:311-20. 2009
    ..Assess the efficacy and tolerability of gabapentin enacarbil (GEn), a transported prodrug of gabapentin with improved gabapentin exposure, in adults with moderate-to-severe primary restless legs syndrome...
  52. doi request reprint Case series of painful legs and moving toes: clinical and electrophysiologic observations
    Maria V Alvarez
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Mov Disord 23:2062-6. 2008
    ..Movements were partially suppressible and were diminished but still apparent during light sleep. GABAergic agents were most effective in controlling the pain and the movements...
  53. ncbi request reprint Parkinsonism, FXTAS, and FMR1 premutations
    Mathias Toft
    Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA
    Mov Disord 20:230-3. 2005
    ..Five patients (1.2%) carry intermediate-size alleles (41-54 CGG repeats). Expansions within the FMR1 gene are not associated with PD in our study...
  54. ncbi request reprint GCH1 in early-onset Parkinson's disease
    Stephanie A Cobb
    Division of Neurogenetics, Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA
    Mov Disord 24:2070-5. 2009
    ..This study does not support a significant role for genetic variation at the GCH1 locus in EOPD. However, our results further highlight the relevance of PRKN screening in familial EOPD...
  55. pmc Genomic investigation of alpha-synuclein multiplication and parkinsonism
    Owen A Ross
    Division of Neurogenetics, Department of Neuroscience, College of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA
    Ann Neurol 63:743-50. 2008
    ..Herein we characterize five families with parkinsonism that have been identified to harbor multiplication of the chromosomal 4q21 locus containing the alpha-synuclein gene (SNCA)...
  56. ncbi request reprint Parkinson's disease and sleep
    Michael J Thorpy
    Sleep Wake Disorders Center, Montefiore Medical Center, Bronx, NY 10467 2490, USA
    Neurol Clin 23:1187-208. 2005
    ..Treatment of sleepiness involves treating any underlying sleep disturbance and may involve the use of stimulant or alerting medications in the daytime...
  57. pmc Research priorities in spasmodic dysphonia
    Christy L Ludlow
    Laryngeal and Speech Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Otolaryngol Head Neck Surg 139:495-505. 2008
    ..To identify research priorities to increase understanding of the pathogenesis, diagnosis, and improved treatment of spasmodic dysphonia...
  58. ncbi request reprint Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology
    Sean J Pittock
    Department of Neurology Mayo Clinic, Rochester, Minnesota 55905, USA
    Mov Disord 19:695-9. 2004
    ..The absence of diagnostic microscopic brain or spinal cord pathology suggests that the pathologic substrate may be neurochemical or receptor based...
  59. ncbi request reprint Time delays prior to movement alter the drawing kinematics of elderly adults
    Diana H Romero
    Motor Control Laboratory, Arizona State University, PEBE Room 107B, Tempe 85287 0404, USA
    Hum Mov Sci 22:207-20. 2003
    ..The findings provide evidence that decays in position sense as a function of time create difficulties in incorporating the initial limb position in motor planning process in elderly adults...
  60. ncbi request reprint Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease
    Mathias Toft
    Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, USA
    Mov Disord 22:389-92. 2007
    ..3; 95% CI: 0.6-2.8; P = 0.45). These findings highlight the importance of using family-based studies and multiple population screenings when examining the association of these polymorphic LRRK2 gene variants with Parkinson's disease...
  61. ncbi request reprint Adaptation to changes in vertical display gain during handwriting in Parkinson's disease patients, elderly and young controls
    Jose L Contreras-Vidal
    Department of Kinesiology and Neuroscience and Cognitive Science Program, University of Maryland, 2363 HHP Building, College Park 20742 2611, USA
    Parkinsonism Relat Disord 9:77-84. 2002
    ..These results may have implications for the treatment of micrographia in Parkinsonism...
  62. ncbi request reprint Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits
    Thomas G Beach
    Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Acta Neuropathol 114:419-24. 2007
    ....
  63. ncbi request reprint Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 23:690-9. 2008
    ..Recognition of factors that impact placebo response rates should be incorporated into individual study designs for PD clinical trials...
  64. ncbi request reprint Genetics of restless legs syndrome
    Ignacio F Mata
    Department of Neuroscience, Mayo Clinic College of Medicine, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Parkinsonism Relat Disord 12:1-7. 2006
    ..Herein, we review the current status of genetics in RLS, providing some methodological guidelines to help future research...
  65. pmc Reduced striatal tyrosine hydroxylase in incidental Lewy body disease
    Thomas Gerald Beach
    Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Acta Neuropathol 115:445-51. 2008
    ..8% (P = 0.01) reduction in ILBD cases, as compared with control cases. The finding suggests that ILBD is not a benign condition but is likely a precursor to PD and/or DLB...
  66. ncbi request reprint Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety study
    Richard M Trosch
    The Parkinson s Disease and Movement Disorders Center, 26400 W, Southfield, Michigan, USA
    Mov Disord 22:1258-64. 2007
    ..Evaluate the safety of botulinum toxin type B (BoNT-B) in subjects with hemifacial spasm (HFS)...